

# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ANALYSIS OF DANOFLOXACIN, DIFLOXACIN, CIPROFLOXACIN AND  
SARAFLOXACIN IN HONEY USING MICELLAR LIQUID CHROMATOGRAPHY AND  
VALIDATION ACCORDING TO THE 2002/657/EC DECISION**

K. Tayeb Cherif, J. Peris-Vicente\*, S. Carda-Broch, J. Esteve-Romero

*Química Bioanalítica, QFA, ESTCE, Universitat Jaume I, 12071, Castelló, Spain*

*\*Corresponding author. E-mail: vicentej@uji.es; Tel.: +34964728099*

**Abstract**

A reliable and a sensitive method based on micellar liquid chromatography was optimized for the analysis of the fluoroquinolones danofloxacin, difloxacin, ciprofloxacin and sarafloxacin in honey. The sample was 1:1 diluted in a 0.05 M sodium dodecyl sulfate solution buffered at pH = 3, thus avoiding an extraction step and the use of toxic chemicals. The fluoroquinolones were resolved in less than 25 min using a C18 column, without interferences from the matrix. The mobile phase was a solution of 0.05 M sodium dodecyl sulfate, 1 % 1-butanol and 0.5 % triethylamine buffered at pH = 3, running under isocratic mode at 1 mL min<sup>-1</sup>. The excitation and emission wavelengths were 280 and 455 nm, respectively. The method was validated in accordance with the European Union Decision 2002/657/EC in terms of: selectivity, sensitivity (limits of detection and quantification, 4 and 10 µg/kg, respectively), calibration range (10-200 µg/kg), linearity ( $r^2 > 0.9990$ ), decision limit (4 µg/kg), detection capability (4.7-6.2 µg/kg), intra- and interday accuracy and precision (81.0 - 103.4 % and < 12.3 %, respectively), and robustness (< 8.5 %). The method was applied to commercial honey samples purchased from a local supermarket.

*Keywords:* Honey; Micellar; Optimization; Fluoroquinolone; Validation

## 1. Introduction

Fluoroquinolones (FQs) are among the most important antibacterial agents and belong to the current arsenal of antibiotics developed against infections<sup>1</sup>. Therefore, these drugs are extensively used in the treatment of human and veterinary bacterial infections due to their effectiveness and broad spectrum of activity. In veterinary medicine, they are specifically used as prophylactic agents to prevent respiratory diseases and bacterial infections in cattle, swine, broiler, turkey, and aquaculture fish<sup>2</sup>. They have been used as anti-infectious agents to treat fowlbrood and nosebleed in bees<sup>3</sup>.

The intensive use of FQ in live animals implies a potential danger for the population. It can stimulate the growing of mutated pathogens resistant to these quinolones, which can lately jump to humans. Besides, drug residues may persist in the edible products of the animals, so that there is concern about the possibility of a continuous and long-term exposure of consumers to high levels of these compounds. As a result, they may unknowingly develop resistance to the quinolones, and would be unaffected by future antibiotic treatments<sup>2</sup>. In the European Union (EU), the presence of these drugs in foodstuff has been regulated through the Commission Regulation (EU) No 37/2010, and maximum residue limits (MRLs) have been established for different food matrices of animal origin<sup>4</sup>. In honey, however, no MRLs have been defined for the fluoroquinolones danofloxacin (log  $P_{o/w}$  = 0.14; pKa = 6.22/9.43)<sup>5</sup>, difloxacin (log  $P_{o/w}$  = 0.77; pKa = 5.66/7.24)<sup>6,7</sup>, ciprofloxacin (log  $P_{o/w}$  = 0.77; pKa = 6.09/8.09)<sup>7,8</sup> and sarafloxacin (log  $P_{o/w}$  = 0.86; pKa = 4.12/6.78)<sup>7</sup>, which structures are shown in Figure 1. The use of FQs is strictly forbidden, and, consequently, the presence of such residues and their metabolites in bee products must be considered as resulting from illegal beekeeping practices<sup>4</sup>. Thus, a honey sample is declared non-compliant if these compounds are detected, and then the corresponding batch would not be allowed to be distributed within the EU.

Honey is world-wide consumed, especially during breakfast, due to its nutritional and health benefits. It is also largely used in the food industry (bakery and cereal-based goods, baby foods, chocolate, *etc.*). Indeed, on a yearly basis, about 1.2 million tons of honey are produced worldwide and 400000 tons are traded internationally<sup>9</sup>. In the last years, the finding of antibiotics in this commodity has had a serious impact on both raw material suppliers and food manufacturers, resulting in rejection and destruction of honey batches and affecting the reputation of the producers. Additionally, this has endangered the image of bee-derived products as healthy and clean. Recently, several FQs were found in honey originating from China, demonstrating that such broad spectrum antibiotics are used by some beekeepers<sup>10</sup>. Therefore, the development of screening methods to check the absence of danofloxacin (DAN), difloxacin (DIF), ciprofloxacin (CIP) and sarafloxacin

(SAR) in honey before they are sent to markets is of the utmost importance to ensure that the batch comply with the EU regulation and to detect a possible threat to the consumers.

Many methods based on separative techniques, such as capillary electrophoresis<sup>11</sup>, thin layer chromatography, gas chromatography and, liquid chromatography<sup>12</sup>, have been developed for the screening of FQs in edible animal tissues. The latest generation of high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) equipment allows the multiresidue determination of these antibiotics in milk<sup>13</sup>, tilapia<sup>14</sup>, and honey<sup>15-20</sup>. However, this equipment is expensive and not all laboratories can afford it. Besides, due to the current situation of economic crisis, the trend points towards the development of inexpensive analytical procedures. Studies have been published on different liquid chromatographic methods based on fluorescence and UV-Visible absorbance detection of FQ in milk<sup>13</sup>, chicken muscle and egg yolk<sup>21</sup>, tissues of food-producing animals<sup>22</sup>, eggs<sup>23</sup>, feeds<sup>24</sup>, livestock and marine products<sup>25</sup> and royal jelly<sup>26</sup>. However, only a few works have been published about the analysis of quinolones in honey using LC-FLD<sup>27,28</sup>. Furthermore, most of the extraction procedures applied to analyze honey require clean-up procedures are tedious and time-consuming, because of the viscosity and the presence of a large amount of sugars. The most usual are liquid/liquid<sup>16,18,19</sup> or solid/liquid<sup>16,20,27,28</sup> extraction, or precipitation of matrix compounds<sup>17,18,20</sup>. In some cases, several consecutive clean-up steps are required<sup>16,18,20</sup> or previous screening by microbiological methods<sup>28</sup>. The enlargement of the experimental procedure increases the probability of loss of analyte, thus reducing the quality of the experimental results. Several authors have proposed the analysis of FQs in honey by an automated on-line sample purification, using turbulent flow chromatography coupled to LC - MS<sup>15</sup>.

Micellar liquid chromatography (MLC), using mobile phases containing an aqueous solution of sodium dodecyl sulfate as surfactant over the critical micellar concentration (CMC) and, eventually, a low amount of a short-chain alcohol, has been applied for the analysis of organic compounds in food<sup>29</sup>. Micellar solutions solubilize both polar and hydrophobic compounds. Thus, samples can be directly injected without risk of precipitation into the column, thus shortening the experimental protocol. As a result, the analysis time, cost and environmental impact are lower than hydroorganic HPLC<sup>30</sup>. Besides, the chromatographic behavior of the analytes in micellar mobile phases is highly stable and reproducible, can be related to the concentration of SDS and alcohol using several equations. Therefore, the composition of the mobile phase can be easily optimized by testing few mobile phases<sup>31</sup>. MLC has been successfully used to analyze the quinolones in fish from fisheries<sup>32</sup>, in eggs and milk<sup>33</sup>.

The aim of this work was to develop an MLC procedure for the screening of DAN, DIF, CIP and SAR in honey. The analytical procedure must be reliable, simple, inexpensive and non-polluting, and useful for the routine analysis of honey samples. The method must be validated

1 following the requirements of the EU Commission Decision 2002/657/EC regulation in terms of  
2 selectivity, linearity, decision limit, detection capability, accuracy, precision, and robustness<sup>34</sup>. The  
3 sensitivity was evaluated through the ICH Harmonized Tripartite Guideline<sup>35</sup>. The procedure  
4 developed would be applied to the analysis of the studied antibiotics in commercial honey samples.  
5  
6  
7  
8  
9

## 10 **2. Experimental**

### 11 *2.1 Standards and chemicals*

12  
13  
14  
15  
16  
17 The solid standards of danofloxacin (purity > 99.9 %), difloxacin (> 99.8 %) and sarafloxacin  
18 (> 97.2 %) were supplied by Fluka (Buchs, SG, Switzerland), whereas ciprofloxacin (> 99.9 %) was  
19 purchased from Sigma (St. Louis, MO, USA).  
20

21  
22 Sodium dodecyl sulfate (> 99.9%) and sodium hydroxide (> 99.0 %) come from Merck  
23 (Darmstadt, Germany). Hydrochloric acid (reagent grade, 37 %), triethylamine (>99.5 %) and  
24 ethanol (HPLC grade) were bought to J.T. Baker (Deventer, the Netherlands). Sodium dihydrogen  
25 phosphate 1-hydrate (99%), 1-propanol, 1-butanol and 1-pentanol (HPLC grade) were obtained  
26 from Scharlab (Barcelona, Spain). Ultrapure water was in-lab generated from distilled water using  
27 an ultrapure water device (Millipore S.A.S., Molsheim, France).  
28  
29  
30  
31  
32

### 33 *2.2 Preparation of solutions and mobile phases*

34  
35  
36  
37 The mobile phases were prepared by weighing the adequate amount of SDS and sodium  
38 dihydrogen phosphate, and solving them in ultrapure water by shaking. The appropriate volume of  
39 triethylamine (TEA) was added to obtain a final concentration of 0.5 % (v/v) and the pH was fixed  
40 to 3 by adding drops of HCl solutions. Furthermore, the organic solvent was added to reach the  
41 desired proportion (% , v/v), and then ultrapure water was added up to the mark of the volumetric  
42 flask. Finally, the solution was ultrasonicated and filtered with the aid of a vacuum pump through a  
43 0.45  $\mu\text{m}$  nylon membrane.  
44  
45  
46  
47

48  
49 Individual stock solutions of the studied FQs were prepared as follows: the adequate quantity  
50 of the solid standard was weighed and solved in few mLs of ethanol, and then filled up with a  
51 micellar solution of 0.05 M SDS at pH 3 (fixed with phosphate buffer), to reach a final  
52 concentration of nearly 100 mg L<sup>-1</sup>. The solution was ultrasonicated to assure the complete  
53 solubilization. These solutions were stored at 4°C in darkness for 1 month. Working solutions were  
54 prepared by successive dilutions with the solution of 0.05 M SDS at pH 3. Working solutions  
55 containing the four fluoroquinolones were prepared by mixing the stock solutions. These solutions  
56  
57  
58  
59  
60

1 were kept at 4°C in darkness for 1 week.  
2  
3

### 4 5 2.3 Chromatographic instrumentation and conditions 6 7

8 The chromatographic system used for this study was a Series HP1100 supplied by Agilent  
9 Technologies (Palo Alto, CA, USA), equipped with an isocratic pump, an autosampler tray and a  
10 fluorescence detector. The stationary phase was in a reverse-phase C18 Kromasil column (150 x 4.6  
11 mm; 5 µm particle size; 10 nm pore size) supplied by Scharlab. The mobile phase was an aqueous  
12 solution of 0.05 M SDS - 1 % (v/v) 1-butanol - 0.5 % (v/v) TEA at pH 3 running under isocratic  
13 mode at room temperature at 1 mL min<sup>-1</sup>. The injection volume was 20 µL. The excitation and  
14 emission wavelengths were set at 280 and 455 nm. The software Agilent Chemstation (Rev.  
15 B.03.01) software was used to control the HPLC instrumentation and to acquire the  
16 chromatographic data. The obtained chromatograms were processed by the Michrom software<sup>36</sup> to  
17 measure the main chromatographic parameters: peak area (A), dead time (t<sub>0</sub>, min), retention time  
18 (t<sub>R</sub>, min), retention factor (k), efficiency (number of theoretical plates, N) and asymmetry (B/A)<sup>37</sup>.  
19 The special care required for the chromatographic system when dealing with micellar mobile phases  
20 is described in<sup>29</sup>.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 32 2.4 Sample collection and processing 33 34

35 Twenty commercial honey samples were purchased in local supermarkets and kept in a fridge.  
36 The trademark, supplier and variety are below indicated:

- 37 - "Granja San Francisco" (Nutrexpa, Barcelona, Spain): multi flower, eucalyptus-lime, forest,  
38 orange blossom.  
39 - "Consum" (Reina Apícola Levantina, Alzira, Spain): multi flower, rosemary, orange blossom,  
40 eucalyptus.  
41 - "El Brezal" (Mielso, Almazora, Spain): orange blossom, rosemary, multi flower, thyme, black  
42 eucalyptus, white eucalyptus, mountain (several mountain flowers), forest (honeydew), acacia,  
43 Yucatan (Nahonal and Dzidzilche flowers).  
44 - "El Quexigal" (El Quexigal, Cebberos, Spain): heather, lavender.

45 All the honey samples were manufactured in Spain, except acacia honey and Yucatan honey,  
46 which were elaborated in Central Europe and Mexico, respectively.  
47

48 The samples were taken out 30 min before the analysis to warm up to room temperature.  
49 Then, 5 g were introduced into a 10 mL-volumetric flask, and filled up with a micellar solution of  
50 0.05 M SDS at pH 3. The diluted solution was filtered through a 0.45 µm nylon membrane, placed  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 into the vials and injected into the chromatographic system. The remaining solutions were not  
2 stored.  
3

4 For spiked samples, the appropriate amount was injected into the honey, immediately before  
5 mixing with the micellar solution.  
6  
7

### 8 9 10 **3. Results and discussion**

#### 11 12 13 *3.1 Optimization of the chromatographic conditions*

14  
15  
16  
17 The main chromatographic conditions (injection volume, 20  $\mu\text{L}$ ; flow-rate, 1  $\text{mL min}^{-1}$ ;  
18 surfactant, SDS; pH, 3; buffer, 0.01 M phosphate and addition of 0.5 % of TEA) were taken from  
19 previously published papers about the analysis of difloxacin and sarafloxacin in fish<sup>32</sup> and  
20 danofloxacin and difloxacin in eggs and milk<sup>33</sup>. These papers also recommend the use of hybrid  
21 mobile phases with a short-chained alcohol to obtain adequate retention times and peak shapes.  
22  
23

24  
25 The composition of the mobile phase (concentration of SDS and organic solvent) and the  
26 detection conditions were optimized. In all the optimization tests, a standard solution of DAN, DIF,  
27 CIP and SAR at 20  $\text{ng L}^{-1}$  was used.  
28  
29

##### 30 31 32 *3.1.1 Selection of the alcohol for the mobile phase*

33  
34  
35 Hybrid mobile phases containing 1-propanol, 1-butanol and 1-pentanol were tested. Using  
36 mobile phases with SDS/1-pentanol, the analytes were barely retained on the C18 column, and then  
37 they overlapped and were eluted too close to the dead time. Therefore, 1-butanol was selected, as  
38 mobile phases using SDS/1-butanol provides better peak shapes and less retention times than using  
39 SDS/1-propanol.  
40  
41

42  
43 The studied range of SDS and 1-butanol amount was between the minimum and maximum  
44 concentration recommended for MLC, 0.05 - 0.15 M, and 1 - 7 %, respectively. In order to evaluate  
45 the chromatographic behavior of each analyte, five mobile phases were tested, at the following SDS  
46 (M)/1-butanol (% v/v): 0.05 - 1; 0.05 - 7; 0.10 - 4; 0.15 - 1 and 0.15 - 7<sup>30</sup>.  
47  
48

49  
50 The chromatographic parameters ( $t_0$ ;  $t_R$ ;  $k$ ; N and B/A) were taken for each FQ and mobile  
51 phase, using the Michrom software<sup>36</sup>. The retention time and the efficiency decrease at higher  
52 concentration of SDS, indicating that the FQ bind to the micelles. On the other hand, at higher  
53 concentrations of 1-butanol, the retention times diminish and the efficiency increase.  
54  
55

##### 56 57 58 *3.1.2 Optimization of the composition of the mobile phase*

The concentration of SDS and 1-butanol were simultaneously optimized following an interpretative strategy, using a chemometrical approach. This mathematical model is based on equations which relate the chromatographic behaviour of the analytes with the composition of the mobile phase<sup>31</sup>. This approach would be more effective and rapid than a sequential (one by one) optimization. The equation (1) is used to describe the retention factor of the analyte, depending on the concentration of SDS ([M]) and 1-butanol ( $\varphi$ ):

$$k = \frac{K_{AS} \frac{1}{1 + K_{AD}\varphi}}{K_{AM}[M] \frac{1 + K_{MD}\varphi}{1 + K_{AD}\varphi}} \quad (1)$$

$K_{AS}$  and  $K_{AM}$  are the partition coefficients of the analyte between the bulk water and stationary phase and the micelle, respectively.  $K_{AD}$  and  $K_{MD}$  measure the relative variation of the analyte in the mobile phase and inside the micelles, because of the presence of the alcohol.  $K_{AM}$  and  $K_{AS}$  depend on the analyte and surfactant, whereas  $K_{AD}$  and  $K_{MD}$  depends of the analyte, the surfactant and the alcohol.

The peak shape is modelled by the equation (2) and can be used to calculate N and B/A. It considers that the distribution of signal  $h(t)$  v.s. elution time follows a modified normal (Gaussian) model, which maximum is at the retention time. The standard deviation is substituted by a linear equation:

$$h(t) = H_0 e^{-0.5 \left( \frac{t-t_R}{s_0 + s_1(t-t_R)} \right)^2} \quad (2)$$

$H_0$  represents the height at the retention time, and depends on the concentration and the fluorescence emission of the analyte. The constant  $s_0$  is a measure of the peak width and  $s_1$  constants quantify the distortion of the peak. The  $s_i$  constants depend on N and B/A and depends on the FQ and the mobile phase.

The chromatographic data obtained by the five mobile phases containing 1-butanol (see section 3.1.1) were processed by the Michrom software<sup>36</sup> as "calibration levels" to fit the equations (1) and (2). Thus, the obtained equations are able to predict  $k$ ; N; B/A and  $h(t)$  for the four FQs in the range 0.05 - 0.15 M (SDS) and 1 - 7 % (1-butanol) by interpolation. Combining these values, the software calculates the resolution ( $r_{ij}$ ) of consecutive peaks following the valley-peak criterion,

1 and the global resolution ( $Z$ ) as the  $r_{ij}$  of the least-resolved peak pair<sup>38</sup>. Besides, theoretical  
2 chromatograms can be drawn by the simultaneous plotting of  $h(t)$  v.s. time for the four analytes.  
3 Thus, the changes in the chromatograms and chromatographic behaviour for each analyte, when the  
4 amount of SDS/butanol progressively varies, can be easily visualized.  
5  
6  
7

8 The concentration of SDS and 1-butanol were selected to obtain the maximum resolution  
9 between the studied FQs at the minimum analysis time. The optimal mobile phase was an aqueous  
10 solution of 0.05 M sodium dodecyl sulfate, 1 % 1-butanol and 0.5 % triethylamine buffered at pH =  
11 3. Under these conditions, the analytes were completely resolved ( $Z = 0.998$ ) in 25 min, and the  
12 peaks were nearly Gaussian. The chromatographic parameters ( $t_R$ ; N; B/A) were: danofloxacin  
13 (15.5; 4201; 1.085), difloxacin (17.6; 1652; 1.012), ciprofloxacin (19.1; 1750; 0.985) and  
14 sarafloxacin (21.4; 3100; 1.047). As required by the 2002/657/EC regulation<sup>34</sup>, the less retained  
15 compound was eluted more than two times the dead times. The errors in the predicted values for  
16 retention factors were < 5 %.  
17  
18  
19  
20  
21  
22

23 The use of a chemometric tool has allowed the optimization of the two parameters testing  
24 only five mobile phases, thus reducing time and effort. The optimized mobile phase has attractive  
25 advantages to apply the method for routine analysis. The use of isocratic mode removes the need  
26 of stabilization time between two injections, thus reducing the total time of analysis. As a result, the  
27 successive analysis of a large amount of samples is expedited and the analysis can be sold at a lower  
28 price. Besides, the optimized mobile phase contains harmless inorganic reagents and a minimal  
29 amount of organic solvent. This reduces the risk of the laboratory staff to handle toxic volatile  
30 solvents and the waste of toxic compounds to the environment.  
31  
32  
33  
34  
35  
36  
37

### 38 3.1.3 Optimization of the detection conditions

39 The studied FQs show an intense fluorescence in micellar media<sup>32,33</sup>. However, the  
40 fluorescence properties can strongly vary depending on the chemical environment, and then spectral  
41 data from other mobile phases and matrices cannot be taken.  
42  
43  
44  
45

46 The excitation and emission spectra of the four drugs were by analyzing a honey sample  
47 spiked with 40  $\mu\text{g}/\text{kg}$  of each antibiotic, using the optimized chromatographic conditions. The  
48 maximum excitation and emission wavelengths (nm) were found similar for the studied analytes:  
49 danofloxacin, 280 and 450; difloxacin, 280 and 455; ciprofloxacin, 285 nm and 465, and  
50 sarafloxacin, 280 nm and 455 nm, respectively. As the spectral data were similar for the studied  
51 fluoroquinolones, the detection conditions were set at intermediate values:  $\lambda_{\text{exc}} = 280$  nm and  $\lambda_{\text{em}}$   
52 = 455 nm. Under these conditions, the four analytes are quantified close to their maximum signal-  
53 to-noise ratio and no changing of detection wavelength during the run was needed.  
54  
55  
56  
57  
58  
59  
60

### 3.2 Sample preparation

Honey sample was mixed with a micellar solution of 0.05 M SDS at pH 3<sup>32</sup> in order to solubilize the saccharides and then obtain a liquid sample with low viscosity. Furthermore, the diluted sample must be filtered to avoid the injection of high particles and remaining aggregates. There is no risk of precipitation after the injection, because the compounds would remain in a micellar medium. The dilution ratio was optimized considering the need of avoiding an early obstruction of the filter before obtaining a volume sufficiently representative of the whole sample, but without excessively diminishing the sensitivity. Several dilution ratios were tested, by varying the amount of honey: 50:1; 20:1; 10:1; 5:1; 1:1. In all cases, an aliquot of 2 mL was easily obtained without obstruction of the filter. Thus, 1:1 was selected to maximize the sensitivity.

A sample of a multi flower honey (trademark "Consum" and manufactured in Spain), free of FQs was analyzed using the optimized method (Figure 2A). Several peaks were observed, but they elute before 10 min and do not interfere with the analytes.

The higher advantage of this experimental procedure is the absence of extraction and clean-up steps, expediting it to a dilution and filtration. Thus, the sample is quantitatively introduced in the chromatographic system. This simplified operating procedure reduces the probability of operator error and strongly shorten the analysis time. As consequence, the possible sources of variability and the risk of loss of analyte are minimized, thus improving the reproducibility. Besides, the analysis can be achieved using a few amount of innocuous reagents, without requiring specific instrumentation and large volumes of toxic organic solvents. This would improve the productivity of the laboratory, the safety for the laboratory staff and lessen the environmental impact of the analysis.

### 3.3 Method validation

The method was validated following the directives of the EU Commission Decision 2002/657/EC<sup>34</sup>. The studied validation parameters were: selectivity, linearity, calibration range, cross over, intra- and interday accuracy and precision, decision limit, detection capability and robustness. The limits of detection and quantification were determined by the ICH Harmonized Tripartite Guideline<sup>35</sup>, as the EU Commission Decision does not mention them. The whole validation was performed using spiked samples of multi flower honey (same as in 3.2), initially free

1  
2 of analytes. The concentrations refer to the w/w amount of FQ in the honey sample, not in injected  
3 aliquot.  
4

### 5 6 7 *3.3.1 Specificity* 8 9

10 The specificity was studied by analyzing the twenty samples of honey described in 2.4. In all  
11 cases, several peaks were detected from the dead time to nearly 5 min, corresponding to the matrix  
12 endogenous compounds. No peaks were observed near the retention times of the analytes, and the  
13 baseline was quite stable at > 10 min. Furthermore, the studied samples were spiked with 40 µg/kg  
14 of each FQ, and analyzed. The resulting chromatograms show similar profile than the blanks, the  
15 only difference was the occurrence of the peaks from the analytes. No overlapping was observed  
16 between the analytes and endogenous compounds. Therefore, the method is enough specific to  
17 unequivocally distinguish the analytes in a wide range of honey varieties.  
18  
19

20 As an example, chromatograms obtained before and after spiking a sample of a multi flower  
21 honey (same as in 3.2) can be seen in Figure 2A and 2B, respectively. Smaller peaks appear from  
22 the dead time to ≈ 10 min, enough far from the elution times of the analytes. The difference  
23 between the retention time of the analytes in standard solution and in spiked samples was < 2.0 %,  
24 and the peak shape was similar.  
25  
26  
27  
28  
29  
30  
31

### 32 33 *3.3.2 Linearity and sensitivity* 34 35 36

37 For calibration purposes, five solutions containing increasing concentrations (three  
38 replicates) of the four studied FQs were analyzed in the 10-200 µg/kg range. The equation relating  
39 the peak area of each analyte and the concentration was adjusted using the least-square linear  
40 regression, in order to calculate the slope and y-intercept. The goodness-of-fit of the data to the  
41 curve was evaluated through the determination coefficient. In order to consider the interday  
42 variability, five calibration curves were constructed in different days over a 3-months period, using  
43 new solutions each time. The average values can be seen in the Table 1. An excellent linearity ( $r^2 >$   
44 0.9990) was obtained for danofloxacin, difloxacin, ciprofloxacin and sarafloxacin in the considered  
45 range.  
46  
47  
48  
49  
50  
51

52 The limit of detection (LOD) and quantification (LOQ) were calculated as the minimal  
53 concentration providing a chromatographic peak 3 or 10 times higher than the baseline noise,  
54 respectively<sup>35</sup>. The LOQ was taken as the minimal level of the calibration curve. The values are  
55 shown in the Table 1. A chromatogram obtained by the analysis of a honey sample spiked at the  
56 LOQ for each analyte is shown in Figure 2C. The low values prove that the method has enough  
57  
58  
59  
60

1 sensitivity to detect low amount of these FQs in honey. These values are similar to those obtained  
2 using other HPLC-FLD-based methods: 4.4  $\mu\text{g}/\text{kg}$ <sup>27</sup> and 7  $\mu\text{g}/\text{kg}$ <sup>28</sup>, using an easier sample  
3 preparation.  
4  
5  
6

### 7 8 9 *3.3.3 Accuracy and precision*

10  
11 The intraday accuracy was calculated as the average value of the concentration measured by  
12 the method (6 successive analyses) and the true value, whereas the intraday precision was  
13 calculated as the relative standard deviation between the obtained peak areas by six successive  
14 injections of the same solution. The same solutions were used for accuracy and precision and,  
15 different to those used in calibration studies. The accuracy and precision of the method were  
16 determined for the four studied FQs at 10; 20 and 40  $\mu\text{g}/\text{kg}$ . The interday values were calculated as  
17 the average of five intraday measurements taken at several days during a three-months period. The  
18 solutions were remade each day. The results are shown in the Table 2.  
19

20 The method was found quite accurate (81.0 - 103.4 %) and precise (< 12.3 %). These values  
21 are in accordance with the EC Decision 2002/657/EC regulation, which accepts values inside 80 -  
22 110 % for accuracy and < 15 % for precision<sup>34</sup>.  
23  
24

### 25 26 27 28 29 30 31 32 *3.3.4 Decision limit and detection capability*

33  
34 The EU Commission Decision 2002/657/EC has introduced the determination of two  
35 validation parameters, the decision limit ( $CC\alpha$ ) and the detection capability ( $CC\beta$ ), which assess the  
36 critical concentrations (detected and really present) above which the method is able to distinguish a  
37 non-compliant sample, considering the method variability and the statistical risk of making a wrong  
38 decision. As no MRLs have been stated for the studied FQs, the samples are non-compliant if the  
39 analytes are detected.  
40  
41

42 The  $CC\alpha$  refers to the detected concentration above which it can be concluded that the  
43 sample is not compliant, with a probability of  $\alpha$  to have a false positive. For compounds without  
44 MRL,  $\alpha = 1\%$ , and the  $CC\alpha$  is taken as the limit of detection.  
45  
46

47 The detection capability ( $CC\beta$ ) is the smallest concentration of FQ in honey samples that  
48 can produce a non-compliant result with a maximal probability of  $\beta$  to make a false negative.  
49 Considering  $\beta = 5\%$ , this value was calculated as the decision limit plus 1.64 times the standard  
50 deviation of a honey sample spiked at the  $CC\alpha$ .  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

CC $\alpha$  and CC $\beta$  values are shown in the Table 1. According to the results, the method is able to notice non-compliant samples in honey batches even containing low concentrations of the studied FQs.

### 3.3.5 Robustness

The robustness was examined by measuring the changes in the retention time and peak area of each FQ, at small, but deliberate variations of the composition of the mobile phase (pH, SDS, 1-butanol, and TEA) and flow rate. These studies were performed using a processed honey sample spiked with 40  $\mu\text{g}/\text{kg}$  of each analyte. The relative standard deviation of the retention time and peak area values, taken at: the optimal value, slightly over and slightly under (each one by three replicates), were calculated. Each parameter was separately studied, maintaining the other constant.

The retention time (< 8.5 %) and the peak area (< 6.5 %) are not significantly affected, when the above-mentioned parameters were modified. The concentration of TEA has the strongest influence on the retention of the analytes, compared to the other parameters. This coincides with that found in a previous paper<sup>32</sup>. Anyway, the method is enough robust to provide consistent results, when the experimental parameters oscillate within a realistic range.

### 3.4 Analysis of real samples

According to the results of the study, the method has been successfully validated following the EU Commission Decision 2002/657/EC, and then could be implemented in laboratories approved for the official residue control of these FQs in honey, or used as a test *prior* sending honey batches to the EU market. Finally, the method was applied to the commercial honey samples described in section 2.4. No significant differences were found in the chromatograms, and the studied fluoroquinolones were not detected.

## 4. Conclusions

The obtained results indicate that micellar liquid chromatography is an interesting alternative to analyze danofloxacin, difloxacin, ciprofloxacin and sarafloxacin in honey. Despite the viscosity of the sample, it can be directly injected after a simple dilution and filtration, thus avoiding tedious and time-consuming extraction procedures, reducing the global analysis time. The studied antibiotics have been eluted using an isocratic mobile phase, without interferences from endogenous compounds of honey. The method was successfully validated following the

1 requirements of the EU Commission Decision 2002/657/EC in terms of selectivity, calibration  
2 range, linearity, accuracy, precision, decision limit, detection capability and robustness. Besides, the  
3 method ensures that a honey sample declared as compliant has only up to  $\mu\text{g}/\text{kg}$  levels of FQ, due to  
4 the use of fluorescence detection. The method uses innocuous inorganic reagents and low  
5 concentration of organic solvent, and then meets the requirements of the "green chemistry".  
6 Besides, it facilitates the successive analysis of a high amount of samples, and it is relatively  
7 inexpensive, thus making it more advantageous. Therefore, the method is applicable to be used for  
8 routine analysis of residues of danofloxacin, difloxacin, ciprofloxacin and sarafloxacin in honey, in  
9 order to evaluate the suitability of the samples to be distributed with the European Union.  
10  
11  
12  
13  
14  
15  
16  
17

## 18 5. Conflict of interest

19  
20  
21  
22 The authors state that there is no financial/commercial conflict of interest.  
23  
24  
25  
26

## 27 6. Acknowledgements

28  
29  
30 This work was supported by Project P1.1B2012-36 del Pla de Promoció de la Investigació  
31 de la Universitat Jaume I.  
32  
33  
34

## 35 7. References

- 36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
1. A. Fàbrega, S. Madurga, E. Giralt, J. Vila, *Microb. Biotechnol.*, 2009, **2**, 40-61
  2. *Emerging and other communicable diseases, surveillance and control. Use of quinolones in food animals and potential impact on human health*, Report of a WHO meeting, World Health Organization, Geneva, Switzerland, 1998. Available at: [http://whqlibdoc.who.int/hq/1998/WHO EMC\\_ZDI\\_98.10.pdf](http://whqlibdoc.who.int/hq/1998/WHO EMC_ZDI_98.10.pdf) (Accessed: 14/06/2015)
  3. W. Reybroeck, E. Daeseleire, H.F. De Brabander, L. Herman, *Vet. Microbiol.*, 2012, **158**, 1–11
  4. European Council, Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin, *OJEU* 2010, **L15**, 1-72. Available at: [http://ec.europa.eu/health/files/eudralex/vol-5/reg\\_2010\\_37/reg\\_2010\\_37\\_en.pdf](http://ec.europa.eu/health/files/eudralex/vol-5/reg_2010_37/reg_2010_37_en.pdf) (Accessed: 14/06/2015)
  5. *Danofloxacin, Environmental Assessment*, Food and Drug Administration, Rockville, MD, USA, 2000. Available at: <http://www.fda.gov/downloads/AnimalVeterinary/Development>

- ApprovalProcess/EnvironmentalAssessments/UCM072389.pdf (Accessed: 14/06/2015)
6. M.H. Abraham, K. Takács-Novák, R.C. Mitchell, *J. Pharm. Sci.*, 1997, **86**, 310-315
  7. A.I. Caço, L.C. Tomé, R. Dohrn, I.M. Marrucho, *J. Chem. Eng. Data*, 2010, **55**, 3160-3163
  8. V. Law, C. Knox, Y. Djoumbou, T. Jewison, A.C. Guo, Y. Liu, A. Maciejewski, D. Arndt, M. Wilson, V. Neveu, A. Tang, G. Gabriel, C. Ly, S. Adamjee, Z.T. Dame, B. Han, Y. Zhou, D.S. Wishart, DrugBank 4.0: shedding new light on drug metabolism, *Nucleic Acids Res.*, 2014, **42**, D1091–S1097, Available at: <http://www.drugbank.ca/> (Accessed: 14/06/2015)
  9. V. Michaud, *Apiacta* 2005, **40**, 52–54. Available at: [http://www.apimondia.com/apiacta/articles/2005/michaud\\_1.pdf](http://www.apimondia.com/apiacta/articles/2005/michaud_1.pdf) (Accessed: 14/05/2015)
  10. *Import Alert IA3604*, Food and Drug Administration, Rockville, MD, USA, 2006. Available at: [http://www.accessdata.fda.gov/cms\\_ia/importalert\\_111.html](http://www.accessdata.fda.gov/cms_ia/importalert_111.html) (Accessed: 14/06/2015)
  11. D. Barrón, E. Jiménez-Lozano, S. Bailac, J. Barbosa, *J. Chromatogr. B*, 2002, **767**, 313-319
  12. J.A. Hernández-Arteseros, J. Barbosa, R. Compañó, M.D. Prat, Analysis of quinolone residues in edible animal products, *J. Chromatogr. A*, 2002, **945**, 1–24
  13. M.P. Hermo, E. Nemitlu, S. Kir, D. Barrón, J. Barbosa, *Anal. Chim. Acta*, 2008, **613**, 98–107
  14. J.A. Paschoal, F.G. Reyes, S. Rath, *Food Addit. Contam. Part A-Chem.*, 2009, **26**, 1331-1340
  15. P. Mottier, Y.A. Hammel, E. Gremaud, P.A. Guy, *J. Agric. Food Chem.*, 2008, **56**, 35-43
  16. R. Galarini, G. Saluti, D. Giusepponi, R. Rossi, S. Moretti, *Food Control*, 2015, **48**, 12-24
  17. J. Wang, D. Leung, *Drug Test. Anal.*, 2012, **4**, 103-111
  18. M. Lombardo-Agüí, A.M. García-Campaña, L. Gámiz-Gracia, C. Cruces-Blanco, *Talanta*, 2012, **93**, 193– 199
  19. M.L. Gómez-Pérez, P. Plaza-Bolaño, R. Romero-González, J.L. Martínez-Vidal, A. Garrido-Frenich, *J. Chromatogr. A*, 2012, **1248**, 130– 138
  20. M.I. Lopez, J.S. Pettis, I.B. Smith, P.S. Chu, *J. Agric. Food Chem.*, 2008, **56**, 1553-1559
  21. E.A. Christodoulou, V.F. Samanidou, I.N. Papadoyannis, *J. Chromatogr. B*, 2007, **859**, 246-255
  22. E.A. Christodoulou, V.F. Samanidou, I.N. Papadoyannis, *J. Sep. Sci.*, 2007, **30**, 2676-2686
  23. J.F. Huang, B. Lin, Q.W. Yu, Y.Q. Feng, *Anal. Bioanal. Chem.*, 2006, **384**, 1228-1235
  24. I. Pecorelli, R. Galarini, R. Bibi, A. Floridi, E. Casciarri, A. Floridi, *Anal. Chim. Acta*, 2003, **483**, 81-89
  25. V. Andreu, C. Blasco, Y. Picó, *TrAC - Trends Anal. Chem.*, 2007, **26**, 534-556
  26. J. Zhou, X. Xue, F. Chen, J. Zhang, Y. Li, L. Wu, L. Chen, J. Zhao, *J. Sep. Sci.*, 2009, **32**, 955-964
  27. Y.I. Yatsukawa, H. Ito, T. Matsuda, M. Nakamura, M. Watai, K. Fujita, Determination of residual fluoroquinolones in honey by liquid chromatography using metal chelate affinity chromatography, *J. AOAC Int.*, 2001, **94**, 1319-1327

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
28. M. Kanda, T. Kusano, S. Kanai, H. Hayashi, Y. Matushima, T. Nakajima, K. Takeba, T. Sasamoto, T. Nagayma, *J. AOAC Int.*, 2010, **93**, 1331-1339
  29. M. Rambla-Alegre, J. Peris-Vicente, S. Marco-Peiró, B. Beltrán-Martinavarró, J. Esteve-Romero, *Talanta*, 2010, **81**, 894–900
  30. J. Peris-Vicente, I. Casas-Breva, P. Roca-Genovés, J. Esteve-Romero, *Bioanalysis*, 2014, **6**, 1975–1988
  31. J. Peris-Vicente, M. Villarreal-Traver, I. Casas-Breva, S. Carda-Broch, J. Esteve-Romero, *J. Sep. Sci.*, 2014, **37**, 2825–2832
  32. M. Rambla-Alegre, J. Peris-Vicente, J. Esteve-Romero, S. Carda-Broch, *Food Chem.*, 2010, **123**, 1294–1302
  33. M. Rambla-Alegre, M.A. Collado-Sánchez, J. Esteve-Romero, S. Carda-Broch, *Anal. Bioanal. Chem.*, 2011, **400**, 1303-1313
  34. European Council, Commission Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results, *OJEC*, 2002, **L221**, 8-36. Available at: <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32002D0657&from=EN> (Accessed: 14/06/2015).
  35. ICH Expert Working Group, *ICH Harmonized Tripartite Guideline: Validation of Analytical procedures, text and methodologies Q2(R1)*, ICH, Geneva, Switzerland, 2005. Available at: [http://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Quality/Q2\\_R1/Step4/Q2\\_R1\\_\\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf) (Accessed: 14/06/2015)
  36. J.R. Torres-Lapasió, *Michrom Software*, Marcel-Dekker, New York, USA, 2000
  37. I. Casas-Breva, J. Peris-Vicente, M. Rambla-Alegre, S. Carda-Broch, J. Esteve-Romero, *Analyst*, 2012, **137**, 4327-4334
  38. J. Peris-Vicente, K. Cherif-Tayeb, P. Roca-Genovés, J. Esteve-Romero, *Madhya Bharti Research Journal*, 2014, LVIII, 1-12

**FIGURE CAPTIONS**

**Figure 1.** Structure of the studied fluoroquinolones.

**Figure 2.** Chromatogram obtained by the analysis of a multi flower honey sample (trademark "Consum", manufactured in Spain): A) blank; B) spiked with a mixture of DAN, DIF, CIP and SAR B) 40 µg/kg, and c) at their corresponding LOQ.

**Table 1.** Calibration parameters for the analytes (Linear range = 10 - 200 µg/kg)





Compound	Slope	Intercept	$r^2$	LOD/CC $\alpha$	LOQ	CC $\beta$
Danofloxacin	2.000 ± 0.004	24.0 ± 0.9	0.9991	4	10	5.5
Difloxacin	3.31 ± 0.03	- 15 ± 8	0.9990	4	10	5.2
Ciprofloxacin	2.64 ± 0.04	-11 ± 9	0.9995	4	10	6.2
Sarafloxacin	1.424 ± 0.008	-2.5 ± 1.7	0.9993	4	10	4.7

n = 5; all concentrations in µg/kg


**Table 2.** Intra- and inter-day accuracy and precision for the studied fluoroquinolones.

Fluoroquinolone	Concentration ( $\mu\text{g}/\text{kg}$ )	Intra-day <sup>a</sup>		Inter-day <sup>b</sup>	
		Accuracy (%)	Precision (RSD, %)	Accuracy (%)	Precision (RSD, %)
Danofloxacin	10	92.7	2.2	95.6	3.4
	20	100.2	0.9	101.2	2.1
	40	100.0	1.9	98.5	1.8
Difloxacin	10	82.3	6.1	87.5	4.5
	20	102.3	6.9	98.5	6.4
	40	99.9	2.8	100.8	4.1
Ciprofloxacin	10	82.1	12.3	86.5	10.2
	20	85.2	3.4	90.5	5.3
	40	99.7	2.2	97.5	2.0
Sarafloxacin	10	81.0	4.9	83.8	5.2
	20	103.4	5.9	101.2	4.6
	40	99.9	3.8	98.6	2.5

<sup>a</sup>n=6; <sup>b</sup>n = 5

**Danofloxacin****Difloxacin****Ciprofloxacin****Sarafloxacin**

Structure of the studied fluoroquinolones  
154x151mm (150 x 150 DPI)



Chromatogram obtained by the analysis of a multi flower honey sample (trademark "Consum", manufactured in Spain): A) blank; B) spiked with a mixture of DAN, DIF, CIP and SAR B) 40 ng/g, and c) at their corresponding LOQ  
165x457mm (150 x 150 DPI)